Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00476229 · ClinicalTrials.gov registry record · NA
Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies
A NA study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT00476229: Completed NA study, sponsored by M.D. Anderson Cancer Center.
NCT00476229 is a NA study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00476229, a NA study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
Primary Objective: 1\. To determine whether the primary endpoint: the composite success rate, defined as the proportion of patients who are alive at day 100; and are without grade 3-4 Graft versus Host Disease (GVHD); and are without grade 4 toxicity (unrelated to infection); and have engrafted, is likely to be at least 40%. Secondary Objectives: 1. To determine the cumulative incidence of chronic graft versus host disease. 2. To determine the overall and disease free survival.
Interventions
- DRUG Rituximab
- DRUG Thymoglobulin
- PROCEDURE Peripheral Blood Stem Cell Infusion
- RADIATION Total Lymphoid Irradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-06 |
| Est. Completion | 2009-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00476229
The ClinicalTrials.gov registry entry for NCT00476229 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Rituximab is the first listed.
NCT00476229 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00476229 about?
NCT00476229 is a clinical study titled "Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies". Primary Objective: 1\. To determine whether the primary endpoint: the composite success rate, defined as the proportion of patients who are alive at day 100; and are without grade 3-4 Graft versus Host Disease (GVHD); and are without grade 4 toxicity (unrelated to infection); and have engrafted, is...
What is the current status of trial NCT00476229?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2006-06. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00476229?
The interventions under investigation include: Rituximab (DRUG), Thymoglobulin (DRUG), Peripheral Blood Stem Cell Infusion (PROCEDURE), Total Lymphoid Irradiation (RADIATION).
Who is sponsoring clinical trial NCT00476229?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.